Beijing-based pharmaceutical research and manufacturing company selling drugs in China.
Beijing-based pharmaceutical research and manufacturing company selling drugs in China.
Moat: none
Headquarters: Beijing, China · Employees: 1,335
Size Beijing Sun-Novo Pharmaceutical Research (688621.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $849M, the 2480th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥51.80 on 18 Nov 2026.
Performance Over six months the shares fell 7.8%, against -18.1% for the median peer and -20.0% for the China market (cap-weighted) — 6th highest of 19 in its peer set.
Growth Revenue fell 0.6% over the last twelve months (peer median +6.6%); the operating margin is -1.8% (peer median 2.7%).
Valuation It trades at 29.0× forward earnings against a peer median of 17.7× (3rd most expensive of 9).
Capital Return on invested capital runs 5.9 points below its cost of capital (7.8% WACC).
Next results Next results expected around 1 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.01B | CN¥1.22B | CN¥1.08B | CN¥931M | CN¥676M |
| Revenue growth | — | +13% | +16% | +38% | — |
| Gross profit | CN¥550M | CN¥634M | CN¥512M | CN¥499M | CN¥358M |
| EBITDA | n/a | CN¥277M | CN¥241M | CN¥255M | CN¥208M |
| Net income | CN¥6.04M | CN¥204M | CN¥177M | CN¥185M | CN¥156M |
| Free cash flow | -CN¥161M | CN¥53.5M | CN¥4.39M | CN¥21.2M | CN¥2.71M |
| Capital expenditure | CN¥50.6M | CN¥42.4M | CN¥30.5M | CN¥73.0M | CN¥104M |
| Total debt | CN¥713M | CN¥613M | CN¥457M | CN¥448M | CN¥259M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688621.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -13.7% | -7.7% | 6th lowest of 21 |
| 6-month return | -7.8% | -18.1% | 6th highest of 19 |
| Distance from 52-week high | -35.8% | -40.2% | 9th highest of 21 |
| Revenue growth (TTM) | -0.6% | +6.6% | 6th lowest of 19 |
| Operating margin | -1.8% | 2.7% | 8th lowest of 19 |
| Forward P/E | 29.0× | 17.7× | 3rd most expensive of 9 |
| ROIC minus cost of capital | -5.9 pp | -2.3 pp | 5th lowest of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Beijing Sun-Novo Pharmaceutical Research 688621.SS | China | $849M | -8% | -1% | -2% | 29.0× | n/a | n/a |
| Jiangsu Yahong Meditech 688176.SS | China | $854M | -20% | +15% | -172% | n/a | n/a | n/a |
| DongKook Pharmaceutical 086450.KS | South Korea | $855M | +9% | +13% | 10% | 14.0× | -4.2% | +10.6% |
| Daewoong Pharm 069620.KS | South Korea | $856M | -33% | +9% | 12% | 9.0× | n/a | n/a |
| Corvus Pharmaceuticals CRVS | United States | $860M | -16% | n/a | n/a | n/a | n/a | n/a |
| Kaken Pharmaceutical 4521.T | Japan | $860M | -8% | +5% | 10% | 21.4× | n/a | n/a |
| City Therapeutics CTY | United States | $861M | n/a | +388% | -442% | n/a | n/a | n/a |
| GuangYuYuan Chinese Herbal Medicine 600771.SS | China | $866M | -26% | -6% | 5% | 38.3× | 31.7% | +4.2% |
| SK Discovery 006120.KS | South Korea | $866M | +25% | +24% | 3% | n/a | n/a | n/a |
| Pharming PHARM.AS | Netherlands | $867M | -6% | +2% | 9% | 34.9× | 2.4% | +12.4% |
| Hunan Er-Kang Pharmaceutical 300267.SZ | China | $829M | -40% | -14% | -29% | n/a | n/a | n/a |
| Sanofi Consumer Healthcare India SANOFICONR.NS | India | $869M | -26% | +23% | 36% | 28.1× | 17.7% | +22.7% |
| Dezhan Healthcare 000813.SZ | China | $825M | -33% | -10% | -121% | n/a | n/a | n/a |
| Zhejiang Ausun Pharmaceutical 603229.SS | China | $824M | -34% | +1% | 0% | n/a | n/a | n/a |
| Wanbangde Pharmaceutical 002082.SZ | China | $823M | -52% | -38% | -10% | n/a | 27.7% | -39.5% |
| Latigo Biotherapeutics LTGO | United States | $882M | n/a | n/a | n/a | n/a | n/a | n/a |
| Hygeia Healthcare 6078.HK | Hong Kong | $811M | -3% | +2% | 14% | 10.4× | 4.6% | +22.5% |
| Collegium Pharmaceutical COLL | United States | $806M | -24% | +8% | 15% | 3.7× | -2.6% | +20.3% |
| Northeast Pharmaceutical 000597.SZ | China | $895M | -14% | -6% | 3% | n/a | -7.6% | -0.7% |
| Aktis Oncology AKTS | United States | $895M | -15% | +337% | -837% | n/a | n/a | n/a |
| Suven Life Sciences SUVEN.NS | India | $803M | -1% | +55% | -4,452% | n/a | n/a | n/a |